DBV Technologies to Report Second Quarter 2024 Financial Results and Business Update on July 30, 2024
Rhea-AI Summary
DBV Technologies (Nasdaq: DBVT), a clinical-stage biopharmaceutical company, has announced it will host a conference call and live audio webcast on Tuesday, July 30th, at 5:30 p.m. ET to discuss its second quarter 2024 financial results and provide a business update. Interested participants can join the call via teleconference or access the live webcast on the company's website. The event details are as follows:
- Teleconference numbers:
United States: +1-877-346-6112
International: +1-848-280-6350
- Webcast: Available on the Investors & Media section of DBV's website
A replay of the presentation will be accessible on the company's website after the event.
Positive
- None.
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, DBVT declined 1.39%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Châtillon, France, July 29, 2024
DBV Technologies to Report Second Quarter 2024 Financial Results and Business Update on July 30, 2024
DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that the Company will host a conference call and live audio webcast on Tuesday, July 30th, at 5:30 p.m. ET to review its second quarter 2024 financial results and provide a business update.
Interested participants may access this call via the below teleconferencing numbers and asking to join the DBV Technologies call:
United States: +1-877-346-6112
International: +1-848-280-6350
A live webcast of the call will be available on the Investors & Media section of the Company’s website: https://www.dbv-technologies.com/investor-relations/. A replay of the presentation will also be available on DBV’s website after the event.
About DBV Technologies
DBV Technologies is a clinical-stage biopharmaceutical company developing treatment options for food allergies and other immunologic conditions with significant unmet medical need. DBV is currently focused on investigating the use of its proprietary technology platform, Viaskin, to address food allergies, which are caused by a hypersensitive immune reaction and characterized by a range of symptoms varying in severity from mild to life-threatening anaphylaxis. Millions of people live with food allergies, including young children. Through epicutaneous immunotherapy (EPIT™), the Viaskin platform is designed to introduce microgram amounts of a biologically active compound to the immune system through intact skin. EPIT is a new class of non-invasive treatment that seeks to modify an individual’s underlying allergy by re-educating the immune system to become desensitized to allergen by leveraging the skin’s immune tolerizing properties. DBV is committed to transforming the care of food allergic people. The Company’s food allergy programs include ongoing clinical trials of Viaskin Peanut in peanut allergic toddlers (1 through 3 years of age) and children (4 through 7 years of age).
DBV Technologies is headquartered in Châtillon, France, with North American operations in Warren, NJ. The Company’s ordinary shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345) and the Company’s ADSs (each representing one ordinary share) are traded on the Nasdaq Global Select Market (Ticker: DBVT).
For more information, please visit www.dbv-technologies.com and engage with us on X (formerly Twitter) and LinkedIn.
Viaskin and EPIT are trademarks of DBV Technologies.
Investor Contact
Katie Matthews
DBV Technologies
katie.matthews@dbv-technologies.com
Media Contact
Angela Marcucci
DBV Technologies
angela.marcucci@dbv-technologies.com
Attachment
FAQ
When will DBV Technologies (DBVT) report its Q2 2024 financial results?
How can investors access DBV Technologies' (DBVT) Q2 2024 earnings call?
Will there be a replay available for DBV Technologies' (DBVT) Q2 2024 earnings presentation?
